Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

As September came to a close, health care stocks had returned about 12% in 2024. But from that point through mid-December, S&P 500 health care stocks plummeted in value as investo ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Over the course of 72 weeks, Lilly tested Zepbound and Wegovy on a population of adults with obesity or patients with "at least one weight-related medical problem and without diabetes." ...

By itself, it’s not enough, but body mass index has years of evidence behind it and still has a place in clinical assessments ...

Eli Lilly is seeking to end a lawsuit filed by ... And in the nearly two years that tirzepatide was in shortage, telehealth companies, medical spas and other clients of compounding pharmacies ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...